The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of radiation and cetuximab followed by irinotecan/cetuximab for children with newly diagnosed diffuse pontine tumors and high-grade astrocytomas.
Margaret Macy
No relevant relationships to disclose
Mark W. Kieran
No relevant relationships to disclose
Susan N. Chi
No relevant relationships to disclose
Kenneth J. Cohen
No relevant relationships to disclose
Tobey MacDonald
No relevant relationships to disclose
Amy A. Smith
No relevant relationships to disclose
Michael Matthew Etzl
No relevant relationships to disclose
Aru Narendran
No relevant relationships to disclose
Lia Gore
No relevant relationships to disclose
Jennifer DiRenzo
No relevant relationships to disclose
Tanya M. Trippett
No relevant relationships to disclose
Nicholas K. Foreman
No relevant relationships to disclose
Ira J. Dunkel
Consultant or Advisory Role - Bristol-Myers Squibb (U)